HighGravityDataBioMarin Pharmaceutical — Aug 4, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000088
Showing in the filing
VOXZOGO country access target
“more than 60 countries”
Period
FY2027
Measure
Company-defined measure
Source
Prose
All guidance in this release · 9
VOXZOGO country access target for FY2027
“more than 60 countries”
VOXZOGO revenue for FY2025
“expected to drive higher VOXZOGO revenue in the second half of 2025 compared to the first half of 2025, and weighted to Q4”
Total Enzyme Therapies revenues for FY2025
“expected to remain robust”
Operating expenses for FY2025
“expected to increase in the second half of 2025 vs. the first half of 2025”
Total Revenues for FY2025
“$3,125 to $3,200”
Non-GAAP Operating Margin % for FY2025
“33% to 34%”
Non-GAAP Diluted EPS for FY2025
“$4.40 to $4.55”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $935 million”
Non-GAAP Diluted EPS assumed Weighted-Averag… for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
Growth • Total VOXZOGO revenue in the second quarter increased 20% compared to the same period in 2024, driven by strong worldwide demand. As of the end of the quarter, children with achondroplasia in 51 countries around the world were being treated with VOXZOGO, representing strong progress towards the company’s target of accessing more than 60 countries by 2027. • Global VOXZOGO Y/Y revenue growth in the quarter was led by U.S. contributions, with the majority of new patient starts in the 0-4 year age group. Outside of the U.S. (OUS), Q2 revenue expansion was supported by deeper penetration in previously opened markets and incremental contributions from new country access. Increasing new patient starts, execution of U.S. expansion initiatives, and ongoing OUS build-out are expected to drive higher VOXZOGO revenue in the second half of 2025 compared to the first half of 2025, and weighted to Q4. • Total Enzyme Therapies revenues grew 15% in the second quarter Y/Y. PALYNZIQ revenue increased 20% Y/Y, and strength in the quarter was driven by greater numbers of patients titrating to daily maintenance dose and strong adherence. VIMIZIM revenue grew 21% Y/Y in the quarter, driven by both ongoing patient demand and order timing. Total Enzyme Therapies revenues in the second half of 2025 are expected to remain robust, despite typical quarter-to-quarter order timing dynamics in the third and fourth quarters. Value Commitment • In the second quarter of 2025, BioMarin delivered expanding margins and increasing profitability. Second quarter
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.